Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
October 27 2023 - 7:45AM
Business Wire
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that
it will report third quarter 2023 financial results on Thursday,
November 2nd, 2023. Mirum will also host a conference call to
discuss the third quarter 2023 financial results and recent
corporate progress.
Conference call details: Thursday, November 2nd, 2023 4:30 p.m.
ET / 1:30 p.m. PT
Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404
975 4839 Passcode: 979561
You may also access the call via webcast by visiting the Events
& Presentations section on Mirum’s website. A replay of this
webcast will be available for 30 days.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare diseases affecting
children and adults. Mirum has three approved medications:
LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid)
capsules, and Chenodal® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of
cholestatic pruritus in patients with Alagille syndrome in the U.S.
(three months and older), in Europe (two months and older), and in
Canada. Mirum has also submitted LIVMARLI for approval in the U.S.
in cholestatic pruritus in PFIC patients three months of age and
older and in Europe in PFIC for patients two months of age and
older. Cholbam is FDA-approved for the treatment of bile acid
synthesis disorders due to single enzyme deficiencies and
adjunctive treatment of peroxisomal disorders in patients who show
signs or symptoms or liver disease. Chenodal has received medical
necessity recognition by the FDA to treat patients with
cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline includes three investigational
treatments for debilitating liver diseases. The LIVMARLI
development program includes the Phase 2b EMBARK study for biliary
atresia. Mirum’s second investigational IBAT inhibitor is
volixibat, which is being evaluated in two potentially
registrational studies including the Phase 2b VISTAS study for
primary sclerosing cholangitis and Phase 2b VANTAGE study for
primary biliary cholangitis. Lastly, Chenodal, is being evaluated
in a Phase 3 clinical study, RESTORE, to treat patients with
CTX.
To learn more about Mirum, visit mirumpharma.com and follow
Mirum on Facebook, LinkedIn, Instagram and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026226565/en/
Investor Contacts: Andrew McKibben ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2024 to May 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From May 2023 to May 2024